AZN - Sesen Bio: Binary Event Approaching

• After years of brewing its medicine, Sesen is poised to gain FDA approval for Vicineum as a treatment for non-muscle-invasive bladder cancer.
• In the VISTA trial, Vicineum demonstrated robust efficacy which trumped all competing molecules.
• Epitomized as a run-up phenomenon, Sesen shares have appreciated over 50% within the past month. And yet, there are more upsides.

For further details see: